Last reviewed · How we verify

Sarcoma Alliance for Research through Collaboration — Portfolio Competitive Intelligence Brief

Sarcoma Alliance for Research through Collaboration pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Air Force Military Medical University, China · 1 shared drug class
  2. Akeso · 1 shared drug class
  3. Astex Pharmaceuticals, Inc. · 1 shared drug class
  4. Centre Leon Berard · 1 shared drug class
  5. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 shared drug class
  6. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  7. Jiangsu ShengDiYa Medicine Co., Ltd. · 1 shared drug class
  8. Nanjing Leads Biolabs Co.,Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sarcoma Alliance for Research through Collaboration:

Cite this brief

Drug Landscape (2026). Sarcoma Alliance for Research through Collaboration — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sarcoma-alliance-for-research-through-collaboration. Accessed 2026-05-16.

Related